First clinical study of a pegylated diabody

Adult Animals Antibodies, Bispecific / administration & dosage Antibodies, Neoplasm / genetics Antigens, Neoplasm / metabolism Antineoplastic Agents / administration & dosage Biological Availability Cell Line, Tumor Dose-Response Relationship, Drug Feasibility Studies Female Humans Infusions, Intravenous Iodine Radioisotopes / administration & dosage Male Mice Neoplasms / diagnosis Positron Emission Tomography Computed Tomography Radiopharmaceuticals / administration & dosage Recombinant Proteins / administration & dosage Single-Chain Antibodies / administration & dosage Tissue Distribution Xenograft Model Antitumor Assays

PET imaging TAG-72 biodistribution first-in-human pegylated diabody

Journal

Theranostics

ISSN: 1838-7640

Titre abrégé: Theranostics

Pays: Australia

ID NLM: 101552395

Informations de publication

Date de publication:
2020

Historique:

received: 12 06 2020

accepted: 14 07 2020

entrez: 14 10 2020

pubmed: 15 10 2020

medline: 2 6 2021

Statut: epublish

Résumé

Through protein engineering and a novel pegylation strategy, a diabody specific to tumor-associated glycoprotein 72 (TAG-72) (PEG-AVP0458) has been created to optimize pharmacokinetics and bioavailability to tumor. We report the preclinical and clinical translation of PEG-AVP0458 to a first-in-human clinical trial of a diabody.

Identifiants

DOI: 10.7150/thno.49422 PMID: 33052222 PMC: PMC7545991

pubmed: 33052222

doi: 10.7150/thno.49422

pii: thnov10p11404

pmc: PMC7545991

doi:

Substances chimiques

Antibodies, Bispecific 0

Antibodies, Neoplasm 0

Antigens, Neoplasm 0

Antineoplastic Agents 0

B72.3 antibody 0

Iodine Radioisotopes 0

Iodine-124 0

Radiopharmaceuticals 0

Recombinant Proteins 0

Single-Chain Antibodies 0

tumor-associated antigen 72 0

Types de publication

Clinical Trial, Phase I Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

11404-11415

Informations de copyright

Déclaration de conflit d'intérêts

Competing Interests: M. Oh was a consultant to Avipep Pty Ltd. Michael J. Wheatcroft was an employee of Avipep Pty Ltd as Research Manager. P.J. Hudson was a consultant to Avipep Pty Ltd as Chief Scientist.

Références

Nat Rev Cancer. 2015 Jun;15(6):347-60

pubmed: 25998714

Bioconjug Chem. 2011 Apr 20;22(4):709-16

pubmed: 21395337

J Clin Oncol. 2015 Aug 20;33(24):2609-16

pubmed: 26124477

Mol Immunol. 2015 Oct;67(2 Pt A):142-52

pubmed: 25934435

J Pharm Sci. 2016 Feb;105(2):460-475

pubmed: 26869412

Clin Cancer Res. 2001 Apr;7(4):1061-72

pubmed: 11309358

Bioconjug Chem. 2019 Apr 17;30(4):1232-1243

pubmed: 30912649

Nucl Med Biol. 2008 Feb;35(2):151-8

pubmed: 18312824

Clin Cancer Res. 2004 Aug 1;10(15):5014-21

pubmed: 15297402

Cancer Res. 2007 Jan 15;67(2):718-26

pubmed: 17234783

Lancet Oncol. 2018 Jun;19(6):825-833

pubmed: 29752180

Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6444-8

pubmed: 8341653

Cancer Res. 1986 Jun;46(6):3118-24

pubmed: 3516392

Ann Surg Oncol. 2004 Feb;11(2):197-202

pubmed: 14761924

J Immunol Methods. 1999 Dec 10;231(1-2):177-89

pubmed: 10648937

AAPS J. 2015 Jan;17(1):134-43

pubmed: 25366889

J Nucl Med. 1995 Apr;36(4):586-92

pubmed: 7699446

Nat Rev Drug Discov. 2018 Mar;17(3):197-223

pubmed: 29192287

J Urol. 1995 May;153(5):1575-9

pubmed: 7536270

Nat Rev Clin Oncol. 2017 Mar;14(3):169-186

pubmed: 27725679

J Clin Oncol. 2015 Aug 20;33(24):2585-7

pubmed: 26169612

J Nucl Med. 1994 Jun;35(6):1017-22

pubmed: 8195861

Aliment Pharmacol Ther. 2004 Dec;20(11-12):1337-46

pubmed: 15606396

J Nucl Med. 2010 Jul;51(7):1139-46

pubmed: 20554731

Cancer. 1997 Dec 15;80(12 Suppl):2458-68

pubmed: 9406696

Nat Biotechnol. 2005 Sep;23(9):1126-36

pubmed: 16151406

J Control Release. 2018 Jun 10;279:126-135

pubmed: 29653224

J Nucl Med. 2018 Sep;59(9):1398-1405

pubmed: 29602820

Pathol Res Pract. 2019 Jan;215(1):171-176

pubmed: 30466765

Cancer Res. 2005 Feb 15;65(4):1471-8

pubmed: 15735035

J Clin Oncol. 2012 Nov 1;30(31):3884-92

pubmed: 22987087

Protein Eng Des Sel. 2006 Apr;19(4):141-5

pubmed: 16436454

Expert Opin Drug Deliv. 2016;13(3):401-19

pubmed: 26654403

J Nucl Med. 2005 Jun;46(6):1023-7

pubmed: 15937315

Nat Commun. 2018 May 4;9(1):1484

pubmed: 29728559

Onco Targets Ther. 2015 Jun 24;8:1567-74

pubmed: 26170691

Adv Ther. 2017 May;34(5):1015-1035

pubmed: 28361465

Antibodies (Basel). 2019 Apr 09;8(2):

pubmed: 31544834

N Engl J Med. 2017 Jan 12;376(2):125-135

pubmed: 28076709

Cancer Res. 1993 Jan 15;53(2):271-8

pubmed: 8417820

J Nucl Med. 2001 May;42(5):764-9

pubmed: 11337573

Nat Rev Cancer. 2012 Mar 22;12(4):278-87

pubmed: 22437872

Nat Rev Clin Oncol. 2017 Nov;14(11):695-707

pubmed: 28675164

Protein Eng Des Sel. 2004 Apr;17(4):315-23

pubmed: 15187222